Two Sigma Advisers LP boosted its stake in shares of Cardiovascular Systems Inc (NASDAQ:CSII) by 4.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,877 shares of the medical device company’s stock after acquiring an additional 1,977 shares during the period. Two Sigma Advisers LP owned 0.15% of Cardiovascular Systems worth $1,827,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in CSII. Balyasny Asset Management LLC acquired a new stake in Cardiovascular Systems during the first quarter worth about $8,071,000. Thrivent Financial for Lutherans raised its position in Cardiovascular Systems by 5.3% during the first quarter. Thrivent Financial for Lutherans now owns 29,501 shares of the medical device company’s stock valued at $1,039,000 after purchasing an additional 1,473 shares in the last quarter. Gabelli Funds LLC lifted its stake in Cardiovascular Systems by 6.2% during the first quarter. Gabelli Funds LLC now owns 147,024 shares of the medical device company’s stock worth $5,177,000 after purchasing an additional 8,645 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cardiovascular Systems by 6.6% in the 1st quarter. Geode Capital Management LLC now owns 591,953 shares of the medical device company’s stock valued at $20,842,000 after purchasing an additional 36,711 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Cardiovascular Systems by 150.7% in the 1st quarter. Janus Henderson Group PLC now owns 1,353,866 shares of the medical device company’s stock valued at $47,670,000 after purchasing an additional 813,837 shares during the last quarter. 92.81% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ CSII opened at $30.99 on Wednesday. The company has a current ratio of 3.29, a quick ratio of 2.80 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $35.83 and a 200-day moving average price of $40.64. Cardiovascular Systems Inc has a 1 year low of $26.00 and a 1 year high of $55.22.
Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings results on Tuesday, May 5th. The medical device company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The business had revenue of $61.18 million for the quarter, compared to analysts’ expectations of $64.00 million. Cardiovascular Systems had a negative net margin of 4.04% and a negative return on equity of 7.36%. On average, research analysts anticipate that Cardiovascular Systems Inc will post -0.81 EPS for the current fiscal year.
Several research firms recently weighed in on CSII. Lake Street Capital reduced their price objective on Cardiovascular Systems from $54.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. BidaskClub lowered shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Tuesday, May 12th. Zacks Investment Research downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating and set a $42.00 target price on the stock. in a research report on Tuesday, May 5th. TheStreet cut shares of Cardiovascular Systems from a “c-” rating to a “d+” rating in a report on Friday, March 13th. Finally, ValuEngine upgraded shares of Cardiovascular Systems from a “hold” rating to a “buy” rating in a report on Wednesday, March 4th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $47.38.
About Cardiovascular Systems
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Recommended Story: What is the strike price in options trading?
Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems Inc (NASDAQ:CSII).
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.